574 related articles for article (PubMed ID: 29551548)
1. Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy.
Peng LC; Narang AK; Gergis C; Radwan NA; Han P; Marciscano AE; Robertson SP; He P; Trieu J; Ram AN; McNutt TR; Griffith E; DeWeese TA; Honig S; Singh H; Greco SC; Tran PT; Deville C; DeWeese TL; Song DY
Urol Oncol; 2018 Jun; 36(6):309.e7-309.e14. PubMed ID: 29551548
[TBL] [Abstract][Full Text] [Related]
2. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
Wong WW; Schild SE; Vora SA; Halyard MY
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
[TBL] [Abstract][Full Text] [Related]
3. End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer.
Narang AK; Trieu J; Radwan N; Ram A; Robertson SP; He P; Gergis C; Griffith E; Singh H; DeWeese TA; Honig S; Annadanam A; Greco S; DeVille C; McNutt T; DeWeese TL; Song DY; Tran PT
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):203-209. PubMed ID: 28094250
[TBL] [Abstract][Full Text] [Related]
4. Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.
Lilleby W; Narrang A; Tafjord G; Vlatkovic L; Russnes KM; Stensvold A; Hole KH; Tran P; Eilertsen K
Radiat Oncol; 2015 Nov; 10():232. PubMed ID: 26577452
[TBL] [Abstract][Full Text] [Related]
5. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.
Beard CJ; Chen MH; Cote K; Loffredo M; Renshaw AA; Hurwitz M; D'Amico AV
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):19-24. PubMed ID: 14697416
[TBL] [Abstract][Full Text] [Related]
6. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy.
Yu HH; Song DY; Tsai YY; Thompson T; Frassica DA; DeWeese TL
Urology; 2007 Jul; 70(1):111-6. PubMed ID: 17656219
[TBL] [Abstract][Full Text] [Related]
7. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
8. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
[TBL] [Abstract][Full Text] [Related]
9. Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy.
Feng FY; Qian Y; Stenmark MH; Halverson S; Blas K; Vance S; Sandler HM; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e361-7. PubMed ID: 21820250
[TBL] [Abstract][Full Text] [Related]
10. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
[TBL] [Abstract][Full Text] [Related]
11. Evidence of perineural invasion on prostate biopsy specimen and survival after radical prostatectomy.
DeLancey JO; Wood DP; He C; Montgomery JS; Weizer AZ; Miller DC; Jacobs BL; Montie JE; Hollenbeck BK; Skolarus TA
Urology; 2013 Feb; 81(2):354-7. PubMed ID: 23374801
[TBL] [Abstract][Full Text] [Related]
12. Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?
Saad A; Goldstein J; Lawrence YR; Spieler B; Leibowitz-Amit R; Berger R; Davidson T; Urban D; Tsang L; Alezra D; Weiss I; Symon Z
Radiat Oncol; 2017 Jan; 12(1):5. PubMed ID: 28061904
[TBL] [Abstract][Full Text] [Related]
13. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
Huang J; Vicini FA; Williams SG; Ye H; McGrath S; Ghilezan M; Krauss D; Martinez AA; Kestin LL
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1141-8. PubMed ID: 22099043
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens.
Maru N; Ohori M; Kattan MW; Scardino PT; Wheeler TM
Hum Pathol; 2001 Aug; 32(8):828-33. PubMed ID: 11521227
[TBL] [Abstract][Full Text] [Related]
15. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
[TBL] [Abstract][Full Text] [Related]
16. Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse.
Laing R; Uribe J; Uribe-Lewis S; Money-Kyrle J; Perna C; Chintzoglou S; Khaksar S; Langley SEM
BJU Int; 2018 Oct; 122(4):610-617. PubMed ID: 29607601
[TBL] [Abstract][Full Text] [Related]
17. Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up.
Lazarev S; Thompson MR; Stone NN; Stock RG
BJU Int; 2018 May; 121(5):781-790. PubMed ID: 29319928
[TBL] [Abstract][Full Text] [Related]
18. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
19. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
[TBL] [Abstract][Full Text] [Related]
20. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
